Form 4: Revolution Medicines Exec Sells Shares Under 10b5-1 Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., executed a pre-planned sale of 25,000 common shares after exercising stock options.

Summary

• Stephen Michael Kelsey, President, Research and Development, of Revolution Medicines, Inc. (RVMD), reported a change in beneficial ownership.
• On October 13, 2025, Kelsey exercised stock options to acquire 25,000 shares of common stock at an exercise price of $4.73 per share.
• Concurrently, Kelsey sold 25,000 shares of common stock at a weighted average price of $48.5416 per share, with individual trades ranging from $48.03 to $48.99.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
• Following these transactions, Kelsey beneficially owns 284,047 shares of common stock, which includes 84,000 restricted stock units.

Sentiment

Score: 6

Explanation: The transaction is a pre-planned insider sale under a 10b5-1 plan, which typically mitigates the negative signal of insider selling. The executive realized a substantial profit, which is positive for the individual, but the reduction in direct equity stake could be viewed neutrally to slightly negatively by some investors.

Positives

• The executive realized a significant profit from exercising options and selling shares, indicating personal financial success.
• The transaction was pre-planned under a Rule 10b5-1 trading plan, which suggests a structured approach to managing personal holdings rather than a reaction to immediate company performance.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces an executive's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the pre-planned nature under a 10b5-1 plan generally reduces its perceived significance compared to an unplanned sale.

Key Dates

Recommendation

While the insider sale by a key executive might typically raise concerns, the transaction was executed under a pre-established 10b5-1 trading plan. This indicates a scheduled liquidation of shares for personal financial planning rather than a reaction to new, undisclosed negative information. Therefore, this single Form 4 filing does not provide sufficient new information to warrant a change from a 'hold' recommendation, assuming the company's fundamentals remain consistent with prior assessments.

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, Insider Trading, Form 4, Stock Option Exercise, 10b5-1 Plan, Biotechnology, Pharmaceuticals